Constantiam Biosciences, a Houston, TX-based startup focused on powering genomic medicine, received $2.05M Phase II SBIR two-year grant from NHGRI.
Constantiam Biosciences is dedicated to advancing genetic variant interpretation and drug discovery through the development of platform engines leveraging high-throughput experimentation and advanced computations.
The company intends to use the amount to support the research and development of its statistical analysis platform, Varify™, which focuses on reclassifying variants of uncertain significance (VUS) at scale by leveraging Multiplexed Assays of Variant Effect (MAVEs).
To complement Varify, Constantiam Biosciences has developed MAVEvidence™, a user-facing application designed for streamlined data presentation and evidence report generation. MAVEvidence will integrate functional analysis results of all MAVEs for cancer genes generated by Varify, enabling automated and scalable variant interpretation. This integration will enhance the efficiency of genetic interpretation and improve patient care by providing clear, actionable insights.
Additionally, the company, led by Norman Ong, added Nicole Persky as Director of Functional Genomics and Kirk Gosik as Director of Computational Biology.
FinSMEs
09/09/2024